

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fisher.

Application No.: To be assigned Examiner: To be assigned

Filed: December 2, 2003 Group Art Unit: To be assigned

For: RECIPROCAL SUBTRACTION DIFFERENTIAL DISPLAY

INFORMATION DISCLOSURE STATEMENT

Express Mail No. ER 589231465US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:


In accordance with 37 C.F.R. § 1.56, Applicant respectfully requests that the references relating to the above-mentioned application and listed in the accompanying PTO-1449 form be made of record in the U.S. Patent and Trademark Office.

Applicant respectfully directs the Examiner's attention to the file history of U.S. Application No. 09/644,460, filed on August 23, 2000, the parent of the instant application, for copies of references which were made of record during prosecution of the parent application. Additional copies of any references will be provided upon request of the Examiner.

Identification of the above-listed references is not to be construed as an admission of the Applicant or the attorneys of the Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the instant application.

Applicant does not believe that any fee is required in connection with this submission. However, should any fee be required, the Commissioner is hereby authorized to charge any such fee to Deposit Account 02-4377. Duplicate copies of this sheet are enclosed.

Dated: December 2, 2003

Respectfully submitted,

By: _____
Peter J. Shen
Patent Office Reg. No. 52,217
Attorney for Applicant
Baker Botts, LLP
(212) 408-2500

Serial No.
To Be Assigned

Applicant
P.B. Fisher

Filing Date
December 2, 2003

Group
To Be Assigned

[illegible][illegible]

	AC		Duigou et al. <i>Suppression of the Progression Phenotype By 5-Azacytidine in Rat Embryo Cells Doubly Transformed by Type 5 Adenovirus and the Has-ras Oncogene.</i> (1989). Annals of the New York Academy of Sciences 567:302-306.
--	----	--	--

Date Considered

***Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
A34587-C-PCT-USA-I
070050.2506

Serial No.
To Be Assigned

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
P.B. Fisher

Filing Date
December 2, 2003

Group
To Be Assigned

AD		Jiang & Fisher. <i>Use of a Sensitive and Efficient Subtraction Hybridization Protocol for the Identification of Genes Differentially Regulated During the Induction of Differentiation in Human Melanoma Cells</i> (1993). Mol. Cell. Different. 1:285-299.
AE		Jiang H. <i>The Melanoma Differentiation Associated Gene mda-7 Suppresses Cancer Cell Growth</i> (1996). Proc. Natl. Acad. Sci. USA 93:9160-65.
AF		Jiang et al. <i>Subtraction Hybridization Identifies a Novel Melanoma Differentiation Associated Gene, mda-7, Modulated During Human Melanoma Differentiation, Growth and Progression</i> (1995) Oncogene 11:2477-86.
AG		Liang & Pardee. <i>Recent Advances in Differential Display</i> (1995). Curr. Opin. Immunol. 1995 7:274-80.
AH		Liang & Pardee. <i>Differential display: A general protocol</i> (1997). Meth. Mol. Biol. 85:3-11.
AI		Liang & Pardee. <i>Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction</i> (1992) Science 257:967-71.
AJ		Shena et al. <i>Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Array</i> (1995). Science 270: 467-70.
AK		Zhang et al. <i>Gene expression profiles in normal and cancer cells</i> (1997). Science 276:1268-72.

Examiner

Date Considered

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.